![2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/Untitled-design-350x250.png)
Artificial intelligence designed drugs Hit 90% Phase I success rate in trials
1. AI-native biotechnology firms are reporting Phase I success rates between 80% and 90%, nearly doubling the historical industry average ...
Tag: Pharma
2MM: AI Roundup- Medtronic’s AI-Robotic Spine Platform, 90% Phase I Success for AI-Designed Drugs, and UCSD’s AI Cancer Risk Predictor [Feb 17th, 2026]
Medtronic Stealth AXiS system integrates AI-robotics for spine care The FDA recently issued a landmark clearance for a surgical platform ...
![CRISPR-mediated gene activation rescues obesity caused by haploinsufficiency [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2019/03/CRISPR-350x250.jpg)
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology
1. Illumina’s Billion Cell Atlas aims to standardize massive CRISPR perturbation data to make biological response patterns more learnable for ...
AstraZeneca moves to own multimodal oncology AI with Modella
1. AstraZeneca is acquiring Modella AI to embed multimodal foundation models into oncology R&D and strengthen biomarker driven trial strategy. ...
NVIDIA and Lilly put $1B behind AI as core drug infrastructure
1. NVIDIA and Eli Lilly plan to invest up to $1B over five years in a joint AI lab to ...
FDA highlights flexible chemistry manufacturing controls expectations for cell and gene therapies
1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, ...
Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates
1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxone‑based therapy ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]
Oral gonorrhea antibiotic Nuzolvence approved just weeks ago The Food and Drug Administration recently approved Nuzolvence (zoliflodacin) as a first‑in‑class ...
2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]
Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated approval to Sodesta, ...
Lilly unveils TuneLab AI platform for biotechs
1. Lilly launched TuneLab on September 9, 2025, giving biotechs access to AI models trained on more than $1 billion ...
